The startup company, located in Wuhan Optical Valley in Hubei Province, claims to have achieved yields of 10 g/kg of rice at a purity of 99,9999 %. A clinical trial is planned from August 2017 at Beijing Tongren Hospital. Presently, the output of rHSA by the company is limited to 1 t/y, but construction of a plant at Xiantao is planned which would provide 40 t of rHSA by 2020. China’s annual demand of HSA is estimated at 420 t, bot domestic production from blood plasma is only about 100 t.

China Bio news release, May 18, 2017